Featured
Read our handpicked blogs, curated for you.
|
Pharma marketers in India know the frustration well. Campaigns stall not because the idea is weak, but because the…
|
For Indian pharma, HCP engagement is no longer about reach; it’s about relevance and measurable impact. Boards want to…
|
Pharma marketing in India is at a turning point. Budgets have expanded, channels have multiplied, and compliance…
Recent releases
|
UCPMP 2024: Making Compliance Invisible with the Right Tech
India’s Department of Pharmaceuticals rolled out Uniform Code for Pharmaceutical Marketing Practices (UCPMP 2024) in March 2024. This isn’t a voluntary guideline anymore, but mandatory. It puts…
|
Tier 2 and Tier 3 Doctors Will Decide India’s Next Pharma Leaders
The Growth Story Nobody Can IgnoreHere’s the truth: the next big wave of pharma growth in India won’t come from metros. It will come from Tier 2 and Tier 3 cities.Chronic therapies like diabetes,…
|
Doctor Experience Is the Competitive Advantage Pharma Isn’t Owning
The Blind Spot in Pharma Marketing: Every pharma CMO knows the usual playbook: more reps, more campaigns, better brand recall. But here’s the blind spot: doctor experience.Not “doctor outreach.” Not…
|
Engagement Lessons Pharma CMOs Should Steal from Netflix
Why Netflix Should Be in Your Next Marketing Meeting. If you think that's a weird question, we have an answer! If you’re a pharma CMO in India, your biggest challenge isn’t reach. It’s relevance…
